About
Technology
Issues
FAQ
Links
Official Page
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.